Kenneth S. Cohen to Lymphoma, Large B-Cell, Diffuse
This is a "connection" page, showing publications Kenneth S. Cohen has written about Lymphoma, Large B-Cell, Diffuse.
Connection Strength
0.272
-
Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2. Cancer. 2019 06 01; 125(11):1830-1836.
Score: 0.144
-
University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL. Br J Haematol. 2018 04; 181(2):264-267.
Score: 0.127